Stock NIRV NIRVANA LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nirvana Life Sciences Inc.

Equities

NIRV

CA6546521064

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 15:01:35 2024-05-22 EDT 		5-day change 1st Jan Change
0.04 CAD -20.00% Intraday chart for Nirvana Life Sciences Inc. -.--% +100.00%
04-02 Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
01-02 Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI

Valuation

Fiscal Period: April 2022 2023
Capitalization 1 4.056 1.021
Enterprise Value (EV) 1 4.02 1.067
P/E ratio -3.68 x -0.68 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -3.75 x -0.98 x
EV / FCF 134,185,866 x -11,881,452 x
FCF Yield 0% -0%
Price to Book -116 x -1.09 x
Nbr of stocks (in thousands) 7,115 34,033
Reference price 2 0.5700 0.0300
Announcement Date 22-08-29 23-10-27
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: April 2021 2022 2023
Net sales - - -
EBITDA 1 -0.6725 -1.073 -1.084
EBIT 1 -0.7012 -1.164 -1.175
Operating Margin - - -
Earnings before Tax (EBT) 1 -0.7346 -5.657 -1.491
Net income 1 -0.7346 -5.654 -1.487
Net margin - - -
EPS 2 -0.0212 -0.1548 -0.0438
Free Cash Flow - 0.03 -0.0898
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 22-03-16 22-08-29 23-10-27
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: April 2021 2022 2023
Net Debt 1 - - 0.05
Net Cash position 1 0.63 0.04 -
Leverage (Debt/EBITDA) - - -0.0424 x
Free Cash Flow - 0.03 -0.09
ROE (net income / shareholders' equity) - -1,106% 271%
ROA (Net income/ Total Assets) - -86.1% -265%
Assets 1 - 6.563 0.5619
Book Value Per Share 2 0.0300 -0 -0.0300
Cash Flow per Share 2 0.0200 0 0
Capex 1 0.55 - -
Capex / Sales - - -
Announcement Date 22-03-16 22-08-29 23-10-27
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NIRVANA LIFE SCIENCES INC. Stock Nirvana Life Sciences Inc.
+100.00% 1.41M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NIRV Stock
  4. Financials Nirvana Life Sciences Inc.